Image 1_Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients.tif

Image 1_Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients.tif

Background<p>For advanced non-small cell lung cancer patients with the epidermal growth factor receptor L858R mutation, the efficacy of the combination of tyrosine kinase inhibitor (TKI) and chemotherapy is suboptimal. Currently, it is unclear whether the combination of bevacizumab, gefitinib,...

Full description

Saved in:
Bibliographic Details
Main Author: Lingli Lei (17293217) (author)
Other Authors: Xiang Zhan (3729154) (author), Jixian Li (10666570) (author), Yi Ding (172783) (author), Jiaxin Li (441199) (author), Fengge Zhou (14095581) (author), Alei Feng (9632702) (author), Xiaomei Li (502923) (author), Zhe Yang (8942) (author)
Published: 2025
Subjects:
Pharmacology
non-small cell lung cancer
epidermal growth factor receptor
bevacizumab
gefitinib
prognosis
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items